Part VI. Antiparasitic treatment for Chagas disease Parte VI. Tratamiento antiparasitario de la enfermedad de Chagas.

Apt, W; Heitmann I.; Jercic I.; Jofre, L; Munoz C Del P.; Noemi, I,; San Martin, A; Sapunar, J; Torres M.; Zulantay I.

Keywords: follow-up, animals, allopurinol, disease, trypanosoma, deficiency, host, classification, humans, human, agents, nifurtimox, agent, benznidazole, immune, nitroimidazoles, drug, article, cruzi, follow, nitroimidazole, guideline, animal, chagas, studies, derivative, immunocompromised, practice, effect, up, antitrypanosomal, Trypanocidal, immunosuppressive


As expert consensus has been arisen about universal antiparasitic treatment for all patients infected with Trypanosoma cruzi, most important drugs licensed for Chagas disease treatment are reviewed: nifurtimox and benznidazol, their mechanisms of action, doses, treatment schedules, adverse effects and contraindications. Two other drugs used for Chagas disease treatment, for which a Chilean experience may be exhibited, are allopurinol and itraconazole. Indications for treatment of Chagas disease in immunocompetent patients and immunocompromised hosts are detailed. This chapter refers besides to the evaluation and monitoring of antiparasitic therapy in immunocompromised patients, the availability of drugs and includes various forms facsimiles suggested to perform clinical and laboratory follow up of patients that undergo treatment, indicating the prescribed drug, adverse effects and time of follow up.

Más información

Volumen: 25
Número: 5
Editorial: Sociedad Chilena de Infectología
Fecha de publicación: 2008